November 2021 Rx Product News

Pharmacy Times, November 2021, Volume 87, Issue 11

Paliperidone Palmitate Extended Release (Invega Hafyera)

Manufactured by Janssen

The FDA has approved paliperidone palmitate extended release (ER) injectable suspension, a twice-a-year treatment for adults with schizophrenia. It is a long-acting atypical antipsychotic injection that offers the fewest doses per year. The injection helps individuals with schizophrenia live without relapses. Before transitioning to the twice-yearly treatment, individuals must be treated with a once-a-month paliperidone palmitate ER injectable suspension (eg, Invega Sustenna) once a month for at least 4 months or a once-every-3-months paliperidone palmitate ER injectable suspension (eg, Invega Trinza) for at least a 3-month cycle.

FOR MORE INFORMATION:

janssen.com

Dihydroergotamine Mesylate Nasal Spray (Trudhesa)

Manufactured by Impel NeuroPharma

Dihydroergotamine mesylate is a nasal spray to treat migraines, with or without auras, in adults. The spray works by entering the vascular-rich upper nasal space and moving into the bloodstream. It provides consistent relief, even hours after the onset of the migraine.

FOR MORE INFORMATION:

impelnp.com

Rivaroxaban (Xarelto) With Aspirin Use

Manufactured by Janssen

The FDA has approved an expanded indication for rivaroxaban to be taken with aspirin for the treatment of lower-extremity revascularization resulting from symptomatic peripheral artery disease (PAD). It is the first treatment for both coronary artery disease and PAD. A regimen of 2.5 mg twice a day with aspirin 100 mg daily has been approved. The medication is used to reduce the risk of major adverse limb and cardiovascular events.

FOR MORE INFORMATION:

janssen.com

Zanubrutinib (Brukinsa)

Manufactured by BeiGene

The FDA has approved zanubrutinib for the treatment of individuals with Waldenström macroglobulinemia. It is a monotherapy treatment used in combination with other therapies to treat various B-cell malignancies. The drug was designed to have sustained inhibition of Bruton tyrosine kinase protein. It is also approved to treat chronic lymphocytic leukemia, mantle cell lymphoma, and other diseases.

FOR MORE INFORMATION:

brukinska.com